The present invention relates to a composition comprising non-water soluble dissacharides and oil, a solvent and at least one pharmaceutical ingredient, wherein the composition contains at least two compounds selected from saccharides and lipid oils such as lactose octabenzoate Methyl hepta-O-isobutyryl-α,β-lactoside, α,β-Lactose octa para-iodobenzoate, 3-iodobenzyl hepta-O-isobutyryl-α,β-lactoside, lactose octapropionate, lactose octaisobutyrate, sucrose octabenzoate, glycerol trihexanoate, Glycerol trioctanoate, Glycerol tridecanoate, Lipiodol, ethyl myristate, ethyl palmitate, ethyl oleoate and wherein the composition is a liquid before administration into the human or animal body and increases in viscosity by more than 2,000 centipoise (cP) after administration.

The present invention relates in a first aspect to a method for the treatment of chronic fatigue syndrome (CFS) comprising administering to a patient in need thereof a therapeutically effective amount of inhibitory or cytotoxic agent against plasma cells. In a further aspect, the present invention relates to a combination of the inhibitory or cytotoxic agent against plasma cells with a B-cell depleting agent or an inhibitor of B-cell activation in the treatment of chron-ic fatigue syndrome. In addition, a combination of an inhibitory or cytotoxic agent against plasma cells and B-Cell depleting agent or an inhibitor of B-cell activation are described. Said combination may be provided in form of a kit comprising suitably effective dosages of said compounds. Further, the use of the compounds or the combination in the treatment of CFS is described.

The present invention relates in a first aspect to a method for the treatment of chronic fatigue syndrome (CFS) comprising administering to a patient in need thereof a therapeutically effective amount of inhibitory or cytotoxic agent against plasma cells. In a further aspect, the present invention relates to a combination of the inhibitory or cytotoxic agent against plasma cells with a B-cell depleting agent or an inhibitor of B-cell activation in the treatment of chron-ic fatigue syndrome. In addition, a combination of an inhibitory or cytotoxic agent against plasma cells and B-Cell depleting agent or an inhibitor of B-cell activation are described. Said combination may be provided in form of a kit comprising suitably effective dosages of said compounds. Further, the use of the compounds or the combination in the treatment of CFS is described.

The present invention relates in a first aspect to a method for the treatment of chronic fatigue syndrome (CFS) comprising administering to a patient in need thereof a therapeutically effective amount of inhibitory or cytotoxic agent against plasma cells. In a further aspect, the present invention relates to a combination of the inhibitory or cytotoxic agent against plasma cells with a B-cell depleting agent or an inhibitor of B-cell activation in the treatment of chron-ic fatigue syndrome. In addition, a combination of an inhibitory or cytotoxic agent against plasma cells and B-Cell depleting agent or an inhibitor of B-cell activation are described. Said combination may be provided in form of a kit comprising suitably effective dosages of said compounds. Further, the use of the compounds or the combination in the treatment of CFS is described.

Compositions comprising satiety peptides (e.g., PYY, PYY(3-36), GLP-1, oxyntomodulin, and cholecystokinin) and DPP-IV inhibitors and methods of treating metabolic diseases with such compositions are provided.

Compositions comprising satiety peptides (e.g., PYY, PYY(3-36), GLP-1, oxyntomodulin, and cholecystokinin) and DPP-IV inhibitors and methods of treating metabolic diseases with such compositions are provided.

A method for treating T-cell acute lymphoblastic leukemia (T-ALL) and other neoplasia with high expression of Notch3 is provided.

A method for treating T-cell acute lymphoblastic leukemia (T-ALL) and other neoplasia with high expression of Notch3 is provided.

This document relates to methods and materials involved in assessing and/or treating mammals (e g , humans) having cancer. For example, methods and materials that can be used to determine whether or not the cancer is likely to be responsive to a particular cancer treatment (e.g., a cancer immunotherapy or a cancer chemotherapy) are provided. For example, methods and materials that can be used to treat a mammal by administering one or more cancer treatments that is/are selected based, at least in part, on whether or not the mammal is likely to be responsive to a particular cancer treatment also are provided.

This document relates to methods and materials involved in assessing and/or treating mammals (e g , humans) having cancer. For example, methods and materials that can be used to determine whether or not the cancer is likely to be responsive to a particular cancer treatment (e.g., a cancer immunotherapy or a cancer chemotherapy) are provided. For example, methods and materials that can be used to treat a mammal by administering one or more cancer treatments that is/are selected based, at least in part, on whether or not the mammal is likely to be responsive to a particular cancer treatment also are provided.